Thalys(SH:603716) Shang Hai Zheng Quan Bao·2025-08-26 19:44Core Viewpoint - The stock of Sairis Medical Technology Group Co., Ltd. has experienced an abnormal trading fluctuation, with a cumulative closing price increase of over 20% in three consecutive trading days, prompting the company to issue a notice regarding this situation [2][3]. Group 1: Stock Trading Abnormality - The company's stock price has deviated significantly, with a cumulative increase of over 20% in three consecutive trading days, which is classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][3]. - The company has conducted a self-examination and confirmed that its production and operational activities are normal, with no significant changes in the market environment or industry policies [4]. Group 2: Verification of Major Events - The company has verified with its controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd., and its actual controller, Mr. Wen Wei, that there are no undisclosed major events that could affect the stock price, including major asset restructuring, share issuance, or significant business cooperation [4]. - There have been no significant media reports or market rumors that could impact the company's stock price, and no other sensitive information has been identified that could affect the stock [5][6]. Group 3: Board of Directors' Statement - The board of directors confirms that there are no undisclosed matters that should be reported according to the Shanghai Stock Exchange rules, and all previously disclosed information is accurate without the need for correction or supplementation [10].